Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies.
about
The potential impact of antifungal drug resistance mechanisms on the host immune response to CandidaClinical perspectives on echinocandin resistance among Candida speciesFitness trade-offs restrict the evolution of resistance to amphotericin BEvaluation of Virulence Factors In vitro, Resistance to Osmotic Stress and Antifungal Susceptibility of Candida tropicalis Isolated from the Coastal Environment of Northeast Brazil.Novel FKS mutations associated with echinocandin resistance in Candida species.In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.Breakthrough invasive candidiasis in patients on micafungin.Calcineurin controls hyphal growth, virulence, and drug tolerance of Candida tropicalis.Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.Micafungin in the treatment of invasive candidiasis and invasive aspergillosisEchinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden.Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.Multicenter study of epidemiological cutoff values and detection of resistance in Candida spp. to anidulafungin, caspofungin, and micafungin using the Sensititre YeastOne colorimetric method.Rapid development of Candida krusei echinocandin resistance during caspofungin therapy.Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis.Rapid emergence of echinocandin resistance during Candida kefyr fungemia treatment with caspofungin.Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrationsInterlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?Recurrent episodes of Candidemia due to Candida glabrata, Candida tropicalis and Candida albicans with acquired echinocandin resistance.Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion MethodCurrent perspectives on echinocandin class drugs.Antifungal drug resistance: do molecular methods provide a way forward?Candidemia in a major regional tertiary referral hospital - epidemiology, practice patterns and outcomes.Antifungal prophylaxis in hematopoietic stem cell transplant recipients: the unfinished tale of imperfect success.Invasive candidiasis and the utility of antifungal susceptibility testing in the ICU.Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches.Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.Antifungal drug resistance among Candida species: mechanisms and clinical impact.Mechanisms of echinocandin antifungal drug resistance.Nosocomial Candidiasis: Antifungal Stewardship and the Importance of Rapid Diagnosis.Echinocandins in antifungal pharmacotherapy.Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin.Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species.Echinocandin Resistance in Candida Species Isolates from Liver Transplant Recipients.Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance.Caspofungin Etest susceptibility testing of Candida species: risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpointsFungal echinocandin resistance.Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans.Improved detection of Candida sp. fks hot spot mutants by using the method of the CLSI M27-A3 document with the addition of bovine serum albumin.
P2860
Q27026751-4AAFECE3-0EB3-4C85-99C1-432F466E78D7Q28082538-E38F479B-A4B7-44D0-89B5-93E8A068E9F3Q28534687-3AC9CAED-0214-4400-B21F-7113EA6EA2FAQ30828568-E5E83847-6811-4563-AAD0-537F7FCF27C1Q33826330-4905EFE2-AC6A-4A9D-9A3B-EBB5FCA0871BQ33876423-7031CF16-F180-4ADC-8DB8-A81CB7146BB8Q33963538-4A19B2A4-4D59-4571-8501-72B2C1A06B6BQ34057053-EA377CB0-D686-444C-B520-2A7E906B1450Q34933267-17C762BB-477D-4FAE-856A-8AAE8DA65D76Q35026516-5E5AA2D8-2717-41F3-81F8-E7D9ADE15FAFQ35140020-E25A6159-907A-485D-83BB-676B75E2187EQ35941237-9C53E417-50AB-4090-9D03-C01D9BCA2A3DQ36158263-A2538D70-B0C2-4222-A8EA-BD699F44E459Q36158489-35A7A92C-AFFF-4825-AA60-FC03323F992DQ36505494-5AFD7A97-EBB4-4773-96FB-C474AD78E43BQ36785949-9917949E-D9EB-4C47-AA41-B20BD7A44FF0Q36856930-7F982F00-D118-4FA4-A403-F5131031211BQ37335747-3C6B3B6A-C40F-4556-94C5-FCC45B9E3A0DQ37500666-10374089-23B7-4EEE-9965-3741F17320E0Q37538775-5042FA80-80FC-4B49-B71A-D9CB371C0EDBQ37554055-B6271D70-ED95-4351-A81A-A459BA06559AQ37554059-9EA81378-9100-4D54-964A-AF90A14AF19EQ37694014-F02030E6-54B7-4947-B46A-FA32D35D537BQ37806065-7F061C77-C087-4CA9-8B13-D85BFF515017Q37867263-C14F1A29-FFE9-4A02-9789-6EF7D8CBF187Q38027469-41BADFF4-6FE6-4F06-B75B-15B90CC5F523Q38236893-4F597D4A-E045-4C76-BA16-79EC94DC4F4EQ38254290-8310AE34-04F0-43DE-A0D6-8402EDE4C855Q38511946-4FB4E1F5-3886-4685-B44D-FDCFBC21FCE1Q38550402-83133706-4C9B-405D-8CA5-C811555DFB77Q38589279-44FAA3FE-F01A-4D3E-91C5-CD31204E19E5Q39458862-7C0BA090-A97F-4563-ACC3-E967A60066F2Q39684445-2A7B42F0-A77F-4990-8890-6295D05058E1Q40345973-8F7E7B0D-E85D-4991-8FBA-6D86C0CBBDB6Q40448192-657D7BA3-68BF-42F5-8A21-FD65F35FD10BQ41184732-08B8CF6D-0457-49D4-8793-5FC847C97A03Q41833091-FB52636E-F72D-4895-B21B-AF407498AE8DQ41848811-FD815E92-C54D-400B-B924-EAE455A2293BQ41990022-7CE6EBA6-19DA-4176-A4C9-4C5E6878B282Q42035300-B1CC8C69-EB1E-4A8E-AD3A-7F757B19B0D9
P2860
Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Caspofungin-resistant Candida ...... for hematologic malignancies.
@en
Caspofungin-resistant Candida ...... for hematologic malignancies.
@nl
type
label
Caspofungin-resistant Candida ...... for hematologic malignancies.
@en
Caspofungin-resistant Candida ...... for hematologic malignancies.
@nl
prefLabel
Caspofungin-resistant Candida ...... for hematologic malignancies.
@en
Caspofungin-resistant Candida ...... for hematologic malignancies.
@nl
P2093
P2860
P356
P1476
Caspofungin-resistant Candida ...... for hematologic malignancies.
@en
P2093
David S Perlin
Dimitrios P Kontoyiannis
Guillermo Garcia-Effron
P2860
P304
P356
10.1128/AAC.00802-08
P407
P577
2008-09-15T00:00:00Z